NICE & SMC
Recommended by the National Institute for Health and Care Excellence (NICE)1
NICE recommends Mulpleo for the treatment of severe thrombocytopenia (TCP) in adults with chronic liver disease (CLD) needing a planned invasive procedure, making the following points in support of its decision:
Mulpleo increases endogenous platelet levels in a predictable and reliable manner, which can help to reduce the requirement for platelet transfusions
The logistics of administering platelet transfusions are onerous, and the option of an oral treatment with a medicinal product can be preferable to both the patient and the NHS
A reduction in platelet transfusions is expected to result in reduced hospital stays, lower risk of delayed/cancelled procedures, and lower risk of transfusion-related complications
Accepted for use by the Scottish Medicines Consortium (SMC)2
SMC has accepted Mulpleo for use in the treatment of severe TCP in adults with CLD needing a planned invasive procedure, making the following points in support of its decision:
Mulpleo could reduce the number of platelet transfusions used, which is beneficial as transfusions can cause adverse events and some patients may become refractory to treatment
The incremental cost-effectiveness ratio (using the SMC’s preferred set of assumptions for the economic modelling) on which this decision was based was £7,737/quality-adjusted life year (QALY)
Patient groups highlighted the convenience of taking a tablet that might avoid multiple transfusions
Overall, the use of Mulpleo will likely save the NHS money, whilst also providing a preferable alternative to platelet transfusions1
References
National Institute for Health and Care Excellence (NICE). Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure. TA617. January 2020. Available at: https://www.nice.org.uk/guidance/ta617. (Accessed January 2022).
Scottish Medicines Consortium (SMC). Lusutrombopag (Mulpleo). December 2019. Available at: https://www.scottishmedicines.org.uk/medicinesadvice/lusutrombopag-mulpleo-full-smc2227/. (Accessed January 2022).
Efficacy
Read about Mulpleo’s proven efficacy across its clinical trials.